Inhibitor Therapeutics (INTI) Net Income towards Common Stockholders (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Net Income towards Common Stockholders came in at -$886425.0 in Q1 2026, down 37.89% YoY from -$1.4 million in Q1 2025, and up 32.12% on a QoQ basis from -$1.3 million in Q4 2025.
Inhibitor Therapeutics (INTI) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$886425.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 37.89% year-over-year to -$886425.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.6 million (down 3.06% YoY) and the FY2025 annual result came in at -$3.3 million, up 1.28% from the prior year.
- Net Income towards Common Stockholders climbed to -$886425.0 in Q1 2026, from -$1.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $12.3 million in Q4 2022 to a low of -$1.5 million in Q4 2024.
- A 5-year average of $61668.9 and a median of -$664760.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 14772.68% — and 2023, when it tumbled 418.93%.
- Tracing INTI's Net Income towards Common Stockholders over 5 years: stood at $12.3 million in 2022, then plunged by 109.47% to -$1.2 million in 2023, then slipped by 24.65% to -$1.5 million in 2024, then advanced by 10.25% to -$1.3 million in 2025, then jumped by 32.12% to -$886425.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$886425.0 (Q1 2026), -$1.3 million (Q4 2025), and -$722184.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | -613,933.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -886,425.00 |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | -722,184.00 |
| Jun 30, 2025 | -693,046.00 |
| Mar 31, 2025 | -642,846.00 |
| Dec 31, 2024 | -1.46 Mn |
| Sep 30, 2024 | -830,957.00 |
| Jun 30, 2024 | -571,690.00 |
| Mar 31, 2024 | -734,711.00 |
| Dec 31, 2023 | -1.17 Mn |
| Sep 30, 2023 | -664,760.00 |
| Jun 30, 2023 | -654,521.00 |
| Mar 31, 2023 | -539,596.00 |
| Dec 31, 2022 | 12.32 Mn |
| Sep 30, 2022 | -128,103.00 |
| Jun 30, 2022 | -127,430.00 |
| Mar 31, 2022 | -148,225.00 |
| Dec 31, 2021 | -83,972.00 |
| Sep 30, 2021 | -121,463.00 |
| Jun 30, 2021 | -116,045.00 |